AKUMS - Akums Drugs and Pharmaceuticals Limited Share Price

During the Q4 FY26 earnings call, the management of Akums Drugs & Pharmaceuticals provided an optimistic outlook with several forward-looking points reflecting their strategy and expectations for growth.

1. Revenue Goals: For the fiscal year 2026, revenue reached INR 4,359 crores, an increase of 5.8% from INR 4,170 crores in FY 2025. The company expects a strong continuation in its performance, with double-digit volume growth anticipated in the CDMO segment, particularly benefiting from the new European and Zambia contracts.

2. European Market Expansion: Following the EU GMP accreditation of their Plant 2, commercial supplies are expected to commence in FY28. The management is targeting approximately EUR 70 million in revenue from the European market by FY28, contributing to an expected 15-16% share of CDMO revenues.

3. Zambia Partnership: Commercial supplies worth approximately $25 million from Indian facilities to Zambia are expected to begin by the end of Q2 FY27, with plans for local manufacturing facilities underway.

4. Margin Improvement: The CDMO margins improved to 14.4% in Q4 FY26, with expectations of continued improvement as the new contracts ramp up. The company anticipates maintaining a similar margin profile moving forward.

5. API Business Outlook: Akums expressed optimism about the API segment, projecting reduced losses in the coming year driven by price increases and a shift towards higher-margin non-cephalosporin products.

6. Long-term Investments: The management signaled ongoing investments in capacity expansions and modernization, with a capex target of INR 300 crores for FY27, aimed at ramping up facilities to support growth.

7. Dividends: The board has proposed a final dividend of INR 1 per share and a special dividend of INR 2 per share, reflecting confidence in sustaining long-term shareholder value.

Management highlighted their proactive approach in navigating challenges and positioned Akums for future growth by leveraging established relationships and enhancing their manufacturing capabilities.

Q1: As your European and regulated market business ramps up, which specific internal capabilities currently least scalable? What concrete investments are being made today?

A1: We acknowledge that regulated markets require stringent capabilities. We're focusing on enhancing our R&D, quality, and regulatory functions. Our experience with large MNC clients has strengthened our operational readiness for these markets. Currently, we have European GMP-approved facilities and are targeting further approvals for various dosage forms in the next 18 months, with investments tied to specific project needs.

Q2: What is the net effect on gross margins considering external pressures and increased complexity?

A2: While external factors like crude-linked inflation impact raw material costs, our business model allows for cost passthrough in CDMO contracts. We have invested over INR 100 crores in R&D to enhance our product offerings, which, alongside increased complexity and specialty markets, supports potential margin improvement despite external pressures.

Q3: Last two quarters had significant volume variance. What is driving this and the outlook?

A3: The volume growth of over 25% has primarily come from existing customers increasing demand for our brands. We anticipate this growth to continue as we target double-digit growth in H1 FY27, despite the overall Indian Pharma Market (IPM) growth remaining low. We expect pricing pressures but maintain a hopeful outlook for sustained volume increases.

Q4: How do you expect the trade generic and API business to perform in FY27? What is the expected tax rate?

A4: Trade generics remain stable but are unlikely to contribute significantly to growth due to their focused strategy. For APIs, we expect improved performance due to rising pricing and targeted exports in Europe, aiming for reduced losses. Our effective tax rate is around 29%, but we anticipate it could normalize closer to 25% as our businesses stabilize.

Q5: What is the capex and future outlook for the injectable facility?

A5: We allocated INR 222 crores in FY26 for capex and aim for INR 300 crores in FY27, focusing on expanding our injectable capabilities. The new facility is currently ramping up, with expectations for significant utilization improvements by the end of this fiscal year.

Q6: How do you manage margins in a volatile API price environment?

A6: Our CDMO business works on a cost-plus model; thus, any fluctuation in API prices directly affects our gross margins. Increasing API prices lead to higher absolute margins since our costs remain fixed, allowing for improved profitability as we optimize our product mix.

Q7: Can you provide an update on the European contract and what to expect in terms of margins?

A7: Our European contract is fixed-price, expected to generate margins in the high teens. We have factored in inflationary pressures in our pricing model, and based on current API costs, we foresee these margins being sustainable.

Q8: What will the contribution from Zambia's operation look like?

A8: The Zambian project represents a $25 million revenue potential over FY27 and FY28, contributing to our top line and aligning with our existing CDMO margins. Once operational, we expect the local facility to further enhance our presence in a growing market.

Q9: With a strong balance sheet, are there specific areas you decided against pursuing?

A9: We've consciously avoided opportunities in metered dose inhalers and oncology injectables due to high investment risks versus expected returns. Additionally, potential acquisitions in branded segments have not aligned with our valuation expectations, leading to careful capital allocation decisions.